Search Results - Ron H.J. Mathijssen

Refine Results
  1. 1

    Blood-based extracellular matrix biomarkers are correlated with clinical outcome after PD-1 inhibition in patients with metastatic melanoma by Stijn L W Koolen, Ron H J Mathijssen, Christina Jensen, Morten Asser Karsdal, Nicholas Willumsen, Joachim Aerts

    Published in Journal for ImmunoTherapy of Cancer (2020-10-01)
    Get full text
    Article


  2. 2

    Feasibility of Extrapolating Randomly Taken Plasma Samples to Trough Levels for Therapeutic Drug Monitoring Purposes of Small Molecule Kinase Inhibitors by Ruben A. G. van Eerden, Esther Oomen-de Hoop, Aad Noordam, Ron H. J. Mathijssen, Stijn L. W. Koolen

    Published in Pharmaceuticals (2021-02-01)
    Get full text
    Article


  3. 3

    Tamoxifen use and potential effects on liver parenchyma: A long‐term prospective transient elastographic evaluation by C. Louwrens Braal, Robert J. deKnegt, Agnes Jager, Stijn L. W. Koolen, Ron H. J. Mathijssen, Karel Eechoute

    Published in Hepatology Communications (2022-09-01)
    Get full text
    Article


  4. 4

    Tumor volume as an alternative response measurement for imatinib treated GIST patients. by Gaia Schiavon, Alessandro Ruggiero, Patrick Schöffski, Bronno van der Holt, Dave J Bekers, Karel Eechoute, Vincent Vandecaveye, Gabriel P Krestin, Jaap Verweij, Stefan Sleijfer, Ron H J Mathijssen

    Published in PLoS ONE (2012-01-01)
    Get full text
    Article


  5. 5

    The Influence of Body Composition on the Systemic Exposure of Paclitaxel in Esophageal Cancer Patients by Leni van Doorn, Marie-Rose B. S. Crombag, Hánah N. Rier, Jeroen L. A. van Vugt, Charlotte van Kesteren, Sander Bins, Ron H. J. Mathijssen, Mark-David Levin, Stijn L. W. Koolen

    Published in Pharmaceuticals (2021-01-01)
    Get full text
    Article


  6. 6

    Combining Sorafenib and Immunosuppression in Liver Transplant Recipients with Hepatocellular Carcinoma by Koen G. A. M. Hussaarts, Leni van Doorn, Sander Bins, Dave Sprengers, Peter de Bruijn, Roelof W. F. van Leeuwen, Stijn L. W. Koolen, Teun van Gelder, Ron H. J. Mathijssen

    Published in Pharmaceuticals (2021-01-01)
    Get full text
    Article


  7. 7

    Capacity and cost benefits of subcutaneous versus intravenous pertuzumab/trastuzumab: The EASE-SC study by Michiel Zietse, Jacky Hu, Esther R. van Staveren, Leontine E.A.M.M. Spierings, Agnes Jager, Birgit C.P. Koch, Ron H.J. Mathijssen, Roelof W.F. van Leeuwen, Frederick W. Thielen

    Published in Breast (2025-12-01)
    Get full text
    Article


  8. 8

    A Metabolomics Approach for Predicting OATP1B-Type Transporter-Mediated Drug–Drug Interaction Liabilities by Yang Li, Yan Jin, Hanieh Taheri, Keith T. Schmidt, Alice A. Gibson, Stefan A. J. Buck, Eric D. Eisenmann, Ron H. J. Mathijssen, William D. Figg, Sharyn D. Baker, Alex Sparreboom, Shuiying Hu

    Published in Pharmaceutics (2022-09-01)
    Get full text
    Article


  9. 9

    Levels of circulating tumor DNA correlate with tumor volume in gastro‐intestinal stromal tumors: an exploratory long‐term follow‐up study by Roos F. Bleckman, Charlotte M. S. C. Haag, Naomi Rifaela, Gerrieke Beukema, Ron H. J. Mathijssen, Neeltje Steeghs, Hans Gelderblom, Ingrid M. E. Desar, Arjen Cleven, Arja terElst, Ed Schuuring, Anna K. L. Reyners

    Published in Molecular Oncology (2024-11-01)
    Get full text
    Article


  10. 10

    Onset and progression of atherosclerosis in patients with melanoma treated with immune checkpoint inhibitors by Ron H J Mathijssen, Arjen Joosse, Daniel Bos, Esther Oomen-De Hoop, Jorie Versmissen, Astrid A M van der Veldt, Daan C H van Dorst, Tom J J Uyl, Timy Andrawes, Alexander HJ Danser

    Published in Journal for ImmunoTherapy of Cancer (2025-04-01)
    Get full text
    Article


  11. 11

    Effects of smoking and body mass index on the exposure of fentanyl in patients with cancer. by Evelien J M Kuip, Wendy H Oldenmenger, Martine F Thijs-Visser, Peter de Bruijn, Astrid W Oosten, Esther Oomen-de Hoop, Stijn L W Koolen, Carin C D Van der Rijt, Ron H J Mathijssen

    Published in PLoS ONE (2018-01-01)
    Get full text
    Article


  12. 12

    Improving the tolerability of osimertinib by identifying its toxic limit by Bram C. Agema, G. D. Marijn Veerman, Christi M. J. Steendam, Daan A. C. Lanser, Tim Preijers, Cor van der Leest, Birgit C. P. Koch, Anne-Marie C. Dingemans, Ron H. J. Mathijssen, Stijn L. W. Koolen

    Published in Therapeutic Advances in Medical Oncology (2022-05-01)
    Get full text
    Article


  13. 13

    Quantitative modeling of tumor dynamics and development of drug resistance in non‐small cell lung cancer patients treated with erlotinib by Anyue Yin, G. D. Marijn Veerman, Johan G. C. vanHasselt, Christi M. J. Steendam, Hendrikus Jan Dubbink, Henk‐Jan Guchelaar, Lena E. Friberg, Anne‐Marie C. Dingemans, Ron H. J. Mathijssen, Dirk Jan A. R. Moes

    Get full text
    Article


  14. 14

    CYP3A4∗22 Genotyping in Clinical Practice: Ready for Implementation? by Tessa A. M. Mulder, Ruben A. G. van Eerden, Mirjam de With, Mirjam de With, Laure Elens, Laure Elens, Laure Elens, Dennis A. Hesselink, Dennis A. Hesselink, Maja Matic, Sander Bins, Ron H. J. Mathijssen, Ron H. N. van Schaik

    Published in Frontiers in Genetics (2021-07-01)
    Get full text
    Article


  15. 15

    Comparison of toxicity and effectiveness between fixed-dose and body surface area-based dose capecitabine by Femke M. de Man, G.D. Marijn Veerman, Esther Oomen-de Hoop, Maarten J. Deenen, Didier Meulendijks, Caroline M.P.W. Mandigers, Marcel Soesan, Jan H.M. Schellens, Esther van Meerten, Teun van Gelder, Ron H.J. Mathijssen

    Published in Therapeutic Advances in Medical Oncology (2019-04-01)
    Get full text
    Article


  16. 16

    Intraperitoneal paclitaxel for patients with primary malignant peritoneal mesothelioma: a phase I/II dose escalation and safety study—INTERACT MESO by Job P van Kooten, Jacobus W A Burger, Cornelis Verhoef, Joachim G J V Aerts, Eva V E Madsen, Alexandra R M Brandt-Kerkhof, Stijn L W Koolen, Ron H J Mathijssen, Michelle V Dietz, Niels A D Guchelaar

    Published in BMJ Open (2022-06-01)
    Get full text
    Article


  17. 17

    Population pharmacokinetics of intraperitoneal irinotecan and SN‐38 in patients with peritoneal metastases from colorectal origin by Pascale C. S. Rietveld, Sebastiaan D. T. Sassen, Niels A. D. Guchelaar, Ruben A. G. vanEerden, Nadine L. deBoer, Teun B. M. van denHeuvel, Jacobus W. A. Burger, Ron H. J. Mathijssen, Birgit C. P. Koch, Stijn L. W. Koolen

    Get full text
    Article


  18. 18

    Semaglutide impairs bioavailability of alectinib: a note of warning based on a cross‐over pharmacokinetic drug‐drug interaction study by Niels Heersche, Daan A. C. Lanser, Esther Oomen‐de Hoop, Attila Içli, Peter deBruijn, Marthe S. Paats, Elisabeth F. C. vanRossum, Stijn L. W. Koolen, Ron H. N. vanSchaik, Anne‐Marie C. Dingemans, G. D. Marijn Veerman, Ron H. J. Mathijssen

    Published in Cancer Communications (2025-08-01)
    Get full text
    Article


  19. 19

    Bioequivalence of alternative pembrolizumab dosing regimens: current practice and future perspectives by Ruben Malmberg, Bram C. Agema, Maaike M. Hofman, Stefani Oosterveld, Sander Bins, Daphne W. Dumoulin, Arjen Joosse, Joachim G. J. V. Aerts, Reno Debets, Birgit C. P. Koch, Astrid A. M. van derVeldt, Roelof W. F. vanLeeuwen, Ron H. J. Mathijssen

    Published in Cancer Communications (2025-04-01)
    Get full text
    Article


  20. 20

    mFast‐SeqS‐based aneuploidy score in circulating cell‐free DNA is a prognostic biomarker in prostate cancer by Khrystany T. Isebia, Bianca Mostert, Teoman Deger, Jaco Kraan, Vanja deWeerd, Esther Oomen‐de Hoop, Paul Hamberg, Brigitte C. M. Haberkorn, Helgi H. Helgason, Ronald deWit, Ron H. J. Mathijssen, Martijn P. Lolkema, Saskia M. Wilting, Job vanRiet, John W. M. Martens

    Published in Molecular Oncology (2023-09-01)
    Get full text
    Article


Search Tools: